(Alliance News) - RTW Biotech Opportunities Ltd on Thursday said the biotech industry is navigating a "complex but increasingly constructive environment" as it reported a decline in its interim net asset value per share. Read More
RTW Biotech Opportunities Ltd - Guernsey, Channel Islands-based investor in high-growth life science sectors - Says it will join the FTSE all-share index on September 22. This follows FTSE Russell's decision to include securities trading in non-sterling currencies. Chair William Simpson says the move "is likely to enhance our exposure to investors, develop greater UK and international investor awareness of RTW Bio, and provide increased long-term access to capital." Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Tuesday noted Aquestive Therapeutics Inc's announcement of a strategic funding agreement with funds managed by RTW Investments LP. Read More
(Alliance News) - Merck & Co Inc on Wednesday said it has struck a deal to acquire Verona Pharma PLC, bolstering its respiratory diseases offering. Read More
(Alliance News) - Water utility Severn Trent and housebuilder Vistry backed guidance, while advertising firm WPP named a new chief executive. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Tuesday highlighted clinical developments from Corxel Pharmaceuticals (Shanghai) Co Ltd, its second-largest portfolio holding, including the start of a US phase 2 trial and positive results from a China study of Corxel's lead obesity treatment, CX11. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Friday provided updates on three of its key listed holdings, highlighting both promising clinical trial results and a significant setback involving one of its biotech investments. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Monday noted investee Rocket Pharmaceuticals has reported "encouraging" data from a phase 1 clinical trial of its treatment for arrhythmogenic cardiomyopathy. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Friday noted positive trial data from investee Artios Pharma, for the ongoing study of its lead candidate ART0380. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Thursday announced a new investment into biotech company Airna, closing its oversubscribed USD155 million series B financing round. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Monday said it underperformed its benchmarks during 2024, while total net asset value climbed following the takeover of Arix Bioscience PLC. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Monday said portfolio company Kailera Therapeutics has received positive results from a recent weight loss treatment trial. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Friday said it has made two separate investments as part of series A and C funding rounds in two clinical-stage firms. Read More
RTW Biotech Opportunities Ltd - investment fund managed by RTW Investments LP that specialises in the life sciences sector - Makes additional investment in Series C extension of Numab Therapeutics, a Swiss clinical stage biotech company focused on the development of multi-specific antibodies in immunology and oncology. Numab's CHF50 million, or USD54.5 million, extension, brought its total Series C funding to CHF180 million. Funds will be used to support its clinical development efforts. RTW Biotech first invested in Numab in May 2021. Read More
(Alliance News) - RTW Biotech Opportunities Ltd said on Friday said it is participating in a EUR65 million Series A financing round for Alesta Therapeutics BV, a Leiden, Netherlands-based biotechnology company focused on developing novel oral therapies for rare diseases with unmet medical needs. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Monday reported two key developments at its Shanghai-based portfolio company Corxel Pharmaceuticals Co Ltd. Read More
RTW Biotech Opportunities Ltd - investment fund managed by RTW Investments LP that specialises in the life sciences sector - Notes Shanghai-based portfolio company Corxel Pharmaceuticals Co Ltd, formerly Ji Xing Pharmaceuticals Ltd, has had its new drug application for Aficamten accepted by China's National Medical Products Administration. Aficamten is a drug treatment for obstructive hypertrophic cardiomyopathy, a genetic heart condition diagnosed in around 130,000 to 330,000 patients in China, in which the heart muscle becomes abnormally thick and limits the heart's pumping function. The drug has also received breakthrough therapy designation from the US Food & Drug Administration. Corxel was founded and launched by RTW Investments in 2019. Read More